A team of psychiatrists has developed new practical guidelines for treating patients suffering from obsessive-compulsive disorder.
A team of psychiatrists has developed new practical guidelines for treating patients suffering from obsessive-compulsive disorder.
The guidelines, published in the Journal of Clinical Psychiatry, are based on surveys of approximately 70 psychiatry and psychology experts. The guidelines make treatment recommendations and rank the available options in order of preference.
This is the third set of guidelines issued by a group led by the Duke University Medical Center. Earlier this year, the psychiatrists made recommendations regarding schizophrenia and bipolar disorder. Solvay Pharmaceuticals funded the project and results were announced at the American Psychiatric Association's annual meeting in San Diego in May.
Intended to standardize treatment and help practitioners prescribe the best treatments for their patients' diseases, the OCD guidelines are more user-friendly than currently available clinical guidelines, according to the researchers. Charts, graphs and colloquial terms describe preferred treatments so that patients can use them as well as doctors.
"A nice feature... is that all of the survey results are illustrated in an easy-to-understand format that allows the clinician to compare his or her own treatment strategies with those favored by experts," said Dr. Allen Frances, head of the Expert Consensus Guidelines Steering Committee and chairman of the department of psychiatry at Duke.
The researchers endorsed cognitive-behavioral therapy as the primary, first-line treatment. Surveyed experts concurred that they recommend weekly CBT sessions with homework assignments or out-of-the-office therapy.
They also agreed that seratonin reuptake inhibitors are the most effective medications for OCD. Four varieties of inhibitors are currently used and the guidelines rate the side effects of the products.
The researchers also stated that pharmacotherapy may be helpful for such as body dysmorphic disorder and bulimia. PR
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.